RespireRx Pharmaceuticals Inc. Announces Appointment of Dr. James Cook and Dr. Jeffrey Witkin as Research Fellows
October 27, 2020 08:55 ET | RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Oct. 27, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
respirerx.jpg
RespireRx Pharmaceuticals Inc. Announces Extension to Long-Term Employment Contract with Tim Jones as President and Chief Executive Officer
August 03, 2020 15:11 ET | RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC: RSPI) (“RespireRx” or the “Company”), is pleased to announce that today, Mr. Tim Jones and RespireRx have...
respirerx.jpg
RespireRx Pharmaceuticals Inc. Announces Appointment of Tim Jones to its Board of Directors
February 03, 2020 09:00 ET | RespireRX Pharmaceuticals Inc.
Glen Rock, N.J, Feb. 03, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...
respirerx.jpg
RespireRx Pharmaceuticals Inc. Secures Clinical and Commercial Supply of Dronabinol for Obstructive Sleep Apnea with the Signing of a Development and Supply Agreement with Noramco, Inc.
September 10, 2018 15:30 ET | RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- September 10, 2018 /Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that on...